Assistive technology company Cognixion has introduced the Cognixion ONE, a breakthrough non-invasive headset designed to enhance mobility and communication for individuals with neurodegenerative conditions. The headset combines artificial intelligence (AI), brain-computer interface (BCI), and augmented reality (AR) technologies to provide a solution for those with limited mobility and communication abilities.
Individuals with conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, and Spinal Muscular Atrophy as well as stroke and traumatic injuries can benefit from the Cognixion ONE. The headset supports various input mechanisms, including head motion, eye gaze, and brain interface, making it accessible to individuals with different capabilities based on their condition’s type and progression. It is a wireless and wearable device that does not require surgery, and its Bluetooth connection allows it to integrate with various accessories and smart home systems.
Andreas Forsland, Founder and CEO of Cognixion, explains that the Cognixion ONE incorporates three promising technologies: Adaptive AI, augmented reality (AR), and brain-computer interface (BCI). The Adaptive AI technology assists individuals with disabilities in interacting more easily with their environment, while augmented reality enables communication between the headset and smart devices. The BCI technology utilizes brainwaves to allow patients with advanced disease progression to interact with the headset, even if they are unable to control their eyes, voice, or body reliably.
Cognixion’s Adaptive AI combines the proprietary ConText engine with personalized language models, which adapt to each individual over time. This technology enables users to interact more quickly and easily with their surroundings, without the need for hands or voice. The Cognixion ONE sets the foundation for advancements in assisting individuals with neurodegenerative conditions and showcases how AI can be tailored for personalized assistance.
The Cognixion ONE received a breakthrough device designation from the US Food and Drug Administration (FDA) in May. This designation allows Cognixion to streamline its development process with the help of feedback from the FDA’s review staff. In addition, Cognixion has obtained accreditation from the US Center for Medicare Services (CMS), recognizing the company’s authorization to sell and be reimbursed for durable medical equipment. Once the FDA clears the Cognixion ONE, which is expected to occur within a year, mass production and sales of the device can begin. This puts Cognixion’s release approximately four years ahead of invasive BCI offerings, providing a significant commercial advantage.
While invasive BCI technology, such as neural implants, receives significant attention and investment, Forsland emphasizes the importance of non-invasive solutions such as the Cognixion ONE. Invasive solutions offer advancements but also come with high healthcare costs and potential risks. Non-invasive devices like the Cognixion ONE provide assistive technology at a fraction of the cost and with reduced risk. Forsland envisions a future where both invasive and non-invasive solutions coexist and can even interact with each other.
The Cognixion ONE offers hope for individuals with neurodegenerative conditions, helping them regain some measure of mobility and communication. With its innovative combination of AI, AR, and BCI technologies, the headset opens up possibilities for more independent living. Cognixion’s breakthrough device designation and CMS accreditation pave the way for future developments in assistive technology, ultimately benefiting individuals living with neurodegenerative conditions.
